MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today)

MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab

Oct. 19, 2007

By Donna Young

MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today)

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.